310: Duchenne gene therapy setback, Alzheimer's drug endorsement & why a STAT reporter buys weed (for journalism)

STAT's Nicholas Florko joins to explain what it means to be a reporter writing about the commercial determinants of health. Hint: Florko's most recent stories focus on weed, vapes, and raw milk. And instead of being chained to a desk, he often drives around to convenience stores and buy bad stuff — all in the name of good journalism. But first, co-hosts Adam Feuerstein and Allison DeAngelis chat about Pfizer's Duchenne gene therapy setback, the likely approval of a new treatment for Alzheimer's disease, and Bob Langer's most recent startup.